首页> 中文期刊> 《肿瘤药学》 >诺维本联合铂类二线化疗治疗老年复发转移性乳腺癌的疗效分析

诺维本联合铂类二线化疗治疗老年复发转移性乳腺癌的疗效分析

         

摘要

目的:观察诺维本联合铂类二线化疗治疗老年复发转移性乳腺癌的临床治疗效果和安全性。方法选取我院收治的老年复发转移性乳腺癌患者78例,随机分为对照组(n=36)和治疗组(n=42)。对照组采用顺铂联合紫杉醇治疗,治疗组采用顺铂联合诺维本治疗,观察和比较两组的临床总有效率和不良反应发生情况。结果对照组和治疗组的总有效率分别为78%、88%,两组比较差异无统计学意义(P>0.05)。对照组和治疗组不良反应的发生率分别为27.8%、9.5%,治疗组显著低于对照组,差异有统计学意义(P<0.05)。结论诺维本联合铂类二线化疗治疗老年复发转移性乳腺癌的效果好,安全性更高,具有临床推广应用价值。%Objective To observe the clinical effects and safety of navelbine plus platinum chemotherapy for second-line metastatic breast cancer in elderly patients. Methods The selected 78 cases of metastatic breast cancer patients were randomly divided into the control group (n=36) and the treatment group (n=42). Patients in the control group were treated with cisplatin plus paclitaxel, and patients in the treatment group were given cisplatin plus navelbine. Observe and compare the clinical ef-ficiency and the occurrence of adverse reactions between the two groups. Results The total efficiency of the control group and the treatment group was 78%and 88%respectively, with no statistical difference (P>0.05). The incidence of adverse reactions was 27.8%in the control group and 9.5%in the treatment group. It was significantly lower in the treatment group than in the control group, and the difference was statistically significant (P<0.05). Conclusion Navelbine plus platinum chemotherapy for second-line treatment of aged metastatic breast cancer patients have good effects and higher security, and deserve clinical application.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号